Charu Kanwal, Ph.D. - Publications

Affiliations: 
2004 University of Utah, Salt Lake City, UT 
Area:
Pharmaceutical Chemistry, Molecular Biology

3/12 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2006 Kakar M, Kanwal C, Davis JR, Li H, Lim CS. Geldanamycin, an inhibitor of Hsp90, blocks cytoplasmic retention of progesterone receptors and glucocorticoid receptors via their respective ligand binding domains. The Aaps Journal. 8: E718-28. PMID 17233535 DOI: 10.1208/Aapsj080481  0.465
2004 Kanwal C, Mu S, Kern SE, Lim CS. Bidirectional on/off switch for controlled targeting of proteins to subcellular compartments. Journal of Controlled Release : Official Journal of the Controlled Release Society. 98: 379-93. PMID 15312994 DOI: 10.1016/J.Jconrel.2004.05.008  0.512
2002 Kanwal C, Li H, Lim CS. Model system to study classical nuclear export signals. Aaps Pharmsci. 4: E18. PMID 12423067 DOI: 10.1208/Ps040318  0.49
Low-probability matches (unlikely to be authored by this person)
2008 Mikaelian I, Coluccio D, Morgan KT, Johnson T, Ryan AL, Rasmussen E, Nicklaus R, Kanwal C, Hilton H, Frank K, Fritzky L, Wheeldon EB. Temporal gene expression profiling indicates early up-regulation of interleukin-6 in isoproterenol-induced myocardial necrosis in rat. Toxicologic Pathology. 36: 256-64. PMID 18413786 DOI: 10.1177/0192623307312696  0.195
2020 Saxena A, Michel LS, Hong Q, Hilsinger K, Kanwal C, Pichardo C, Goswami T, Santin A. TROPiCS–03: A phase II open-label study of sacituzumab govitecan (SG) in patients with metastatic solid tumors. Journal of Clinical Oncology. 38: TPS3648-TPS3648. DOI: 10.1200/jco.2020.38.15_suppl.tps3648  0.104
2010 Mikaelian I, Buness A, de Vera-Mudry MC, Kanwal C, Coluccio D, Rasmussen E, Char HW, Carvajal V, Hilton H, Funk J, Hoflack JC, Fielden M, Herting F, Dunn M, Suter-Dick L. Primary endothelial damage is the mechanism of cardiotoxicity of tubulin-binding drugs. Toxicological Sciences : An Official Journal of the Society of Toxicology. 117: 144-51. PMID 20624997 DOI: 10.1093/Toxsci/Kfq189  0.094
2011 Mikaelian I, Buness A, Hirkaler G, Fernandes R, Coluccio D, Geng W, Visalli T, Bachynsky MO, Berkofsky-Fessler W, Kanwal C, Hilton H, Nicklaus R, Hoflack JC, Dunn M, Sanders M, et al. Serum cardiac troponin I concentrations transiently increase in rats given rosiglitazone. Toxicology Letters. 201: 110-5. PMID 21172411 DOI: 10.1016/j.toxlet.2010.12.012  0.091
2009 Berkofsky-Fessler W, Nguyen TQ, Delmar P, Molnos J, Kanwal C, DePinto W, Rosinski J, McLoughlin P, Ritland S, DeMario M, Tobon K, Reidhaar-Olson JF, Rueger R, Hilton H. Preclinical biomarkers for a cyclin-dependent kinase inhibitor translate to candidate pharmacodynamic biomarkers in phase I patients. Molecular Cancer Therapeutics. 8: 2517-25. PMID 19755512 DOI: 10.1158/1535-7163.Mct-09-0083  0.075
2015 Rodon J, Rosenthal M, Mason W, Segura PP, Beck JT, Hirte H, DeGroot JF, Trandafir L, Pognan N, Yang L, Kanwal C, Wen PY. ATNT-12PHASE I, TWO-STAGE, OPEN-LABEL, DOSE-ESCALATION STUDY OF BUPARLISIB (BKM120) IN COMBINATION WITH ADJUVANT TEMOZOLOMIDE (TMZ) AND WITH CONCOMITANT RADIATION THERAPY (RT) AND TMZ IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM) Neuro-Oncology. 17: v12.4-v13. DOI: 10.1093/neuonc/nov205.12  0.073
2020 Petrylak DP, Tagawa ST, Jain RK, Bupathi M, Balar AV, Rezazadeh A, George S, Palmbos PL, Nordquist LT, Davis NB, Vogelzang NJ, Ramamurthy C, Sternberg CN, Loriot Y, Agarwal N, ... ... Kanwal C, et al. Early results of TROPHY-U-01 Cohort 2: Sacituzumab govitecan (SG) in platinum-ineligible patients (pts) with metastatic urothelial cancer (mUC) who progressed after prior checkpoint inhibitor (CPI) therapy. Journal of Clinical Oncology. 38: 5027-5027. DOI: 10.1200/jco.2020.38.15_suppl.5027  0.069
2019 Tagawa S, Balar A, Petrylak D, Grivas P, Agarwal N, Sternberg C, Hong Q, Gladden A, Kanwal C, Siemon-Hryczyk P, Goswami T, Itri L, Loriot Y. Initial results from TROPHY-U-01: A phase II open-label study of sacituzumab govitecan in patients (Pts) with metastatic urothelial cancer (mUC) after failure of platinum-based regimens (PLT) or immunotherapy Annals of Oncology. 30: v890-v891. DOI: 10.1093/annonc/mdz394.049  0.043
2013 Gimbun J, Ali S, Kanwal CCSC, Shah LA, Hidayah N, Cheng CK, Nurdin S. Biodiesel production from rubber seed oil using activated cement clinker as catalyst Procedia Engineering. 53: 13-19. DOI: 10.1016/j.proeng.2013.02.003  0.042
Hide low-probability matches.